Thursday, May 11, 2023 11:10:15 AM
Biotechs are attractive targets for this kind of activity because their bread and butter is in the hard sciences (not you theranos et al) so it's difficult for investors who don't have a very focused intense education in the field to determine for themselves whether a company's technology has potential... they have to rely on the company's marketing or, their competitors attacks- both heavily biased at best, deceptive at worst. It's easy to influence people without a cellar biology background, and they're more likely to err towards caution when someone throws up the buyer beware flag; they can't tell if it's not justified.
The Bullshit Asymmetry Principle: Brandolini's Law:
THE AMOUNT OF ENERGY REQUIRED TO REFUTE BULLSHIT IS AN ORDER OF MAGNITUDE GREATER THAN THE ENERGY NEEDED TO PRODUCE IT.
[chart]investor
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM